Carisma Takes Its CAR-M Approach In Solid Tumors Public Via Sesen Merger

 
• By Joseph Haas

Merging with the shell of troubled cancer biotech Sesen, Carisma believes its chimeric antigen-receptor-macrophage (CAR-M) platform can bring the immunotherapy application to solid tumors.

TME
Carisma says CAR-M therapies can work effectively in the tumor microenvironment • Source: Shutterstock

More from Deals

More from Business